Key facts
- This page summarizes Deborah Knobelman's Form 4 filing for Senti Biosciences, Inc. (SNTI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2024, 17:24.
Deborah Knobelman - 01 Feb 2024 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)
- Reporting relationship
- Chief Financial Officer, Head of Corporate Development
- Issuer ticker
- SNTI
- Reported as of
- 01 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2024, 17:24:38 UTC
- Prior SEC filing
- 02 Feb 2023
- Next SEC filing
- 04 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mike Rhee, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Deborah Knobelman filed Form 4 for Senti Biosciences, Inc. (SNTI) on 02 Feb 2024.
Change
- Previous filing in this sequence was filed on 02 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SNTI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +101,000
- Change %
- +337%
- Price
- $0.000000
- Shares after
- 131,000
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SNTI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +152,000
- Change %
- Price
- $0.000000
- Shares after
- 152,000
- Date
- 01 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 152,000
- Exercise price
- $0.4600
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.
Footnote F2
The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.